الفهرس 
CHRONIC LYMPHOCYTIC LEUKEMIA
Anemia and thrombocytopeniaOnly 14 pages are availabe for public view
 |  | from | 87 |  |  |
| | | from | 87 | | |
Abstract
B-cell chronic lymphocytic leukemia (B-CLL) results from accumulation of small mature B lymphocytes which have undergone monoclonal expansion in blood, bone marrow and lymphoid organs which is mainly due to inhibition of apoptosis rather than enhanced cell proliferation. CLL has a typical clinical presentation with highly heterogenous clinical course. Some patients never require a theraputic intervention while the survival of other patients is short despite early initiation of therapy. LAIR-1 (also known as CD305) belongs to the family of immune inhibitory receptors, which are involved in controlling the balance of the immune system to prevent improper activation or over activation, which may result in tissue damage or autoimmune diseases. LAIR1 is a transmembrane glycoprotein that acts as an inhibitory receptor and is expressed on almost all immune cells, including NK cells, T cells, B cells and monocytes, monocytederived dendritic cells, eosinophils, basophils, mast cells, CD34 +ve hematopoietic progenitor cells and on the majority of thymocytes. LAIR-1 inhibits survival and proliferative signals in leukaemic cells and prevent CLL division. The aim of this work was to study the role of LAIR1 expression in CLL patients, and its relation with other prognostic markers.